TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
TherapeuticsMD's ebitda for the twelve months ending Jun 30, 2026 was -$3.57M. For fiscal 2025 it was -$4.01M. The highest annual figure on record is $2.38M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.01M | – |
| FY2024 | Dec 31, 2024 | -$5.60M | – |
| FY2023 | Dec 31, 2023 | -$7.60M | -418.8% |
| FY2022 | Dec 31, 2022 | $2.38M | – |
| FY2021 | Dec 31, 2021 | -$78.84M | – |
| FY2020 | Dec 31, 2020 | -$151.47M | – |
| FY2019 | Dec 31, 2019 | -$149.81M | – |
| FY2018 | Dec 31, 2018 | -$129.93M | – |
| FY2017 | Dec 31, 2017 | -$77.42M | – |
| FY2016 | Dec 31, 2016 | -$90.12M | – |
| FY2015 | Dec 31, 2015 | -$85.13M | – |
| FY2014 | Dec 31, 2014 | -$53.99M | – |
| FY2013 | Dec 31, 2013 | -$25.75M | – |
| FY2012 | Dec 31, 2012 | -$16.09M | – |
| FY2011 | Dec 31, 2011 | -$5.37M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$721.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$629.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$766.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$599.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$552.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$974.00K | -102.0% |
| Q3 FY2023 | Sep 30, 2023 | -$1.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.64M | – |
| Q4 FY2022 | Dec 31, 2022 | $48.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.25M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$38.89M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.26M | – |
| Q4 FY2020 | Dec 31, 2020 | -$33.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$44.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$49.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$43.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$26.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$38.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$38.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -$32.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.66M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.62M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.78M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.89M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.09M | – |
See a number that looks wrong?